Prophylaxis and treatment of fungal infections associated with haematological malignancies

Related Experiment Video

Updated: Oct 3, 2026

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

S Ascioglu1, B E de Pauw, J F Meis

  • 1Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey.

International Journal of Antimicrobial Agents
|August 5, 2000
PubMed

Insights

Hematological malignancy patients face high infection risks, especially during neutropenia. This review examines antifungal therapies, including new formulations of Amphotericin B and itraconazole, for systemic fungal infections.

Area of Science:

  • Medical Mycology
  • Hematology
  • Infectious Diseases

Background:

  • Patients with hematological malignancies are highly susceptible to microbial infections, particularly during neutropenia.
  • There is a rising incidence of invasive fungal infections, necessitating improved diagnostics and antifungal treatments.
  • Current antifungal agents have limitations, such as Amphotericin B's toxicity and need for IV administration, and oral agents' narrow spectrum (fluconazole) or absorption issues (itraconazole capsules).

Purpose of the Study:

  • To review prophylactic and treatment strategies for systemic fungal infections in immunocompromised patients.
  • To discuss the specific antifungal needs of patients with different types of leukemia.
  • To examine the advantages of novel Amphotericin B and itraconazole formulations.

Main Methods:

  • Literature review of prophylactic and treatment options for systemic fungal infections.
  • Analysis of current antifungal therapies and their limitations.
  • Evaluation of new drug formulations for Amphotericin B and itraconazole.

Main Results:

  • Invasive fungal infections are a significant concern in hematological malignancy patients.
  • Limitations exist with current standard antifungal therapies, driving the need for alternatives.
  • New formulations of Amphotericin B and itraconazole show promise in addressing existing therapeutic challenges.

Conclusions:

  • Optimizing antifungal prophylaxis and treatment is crucial for patients with hematological malignancies.
  • Addressing the limitations of current antifungals requires exploring new formulations and therapeutic approaches.
  • Individualized treatment strategies considering leukemia type and drug formulation benefits are essential for effective fungal infection management.

More Related Videos

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Colony-Forming Unit Assay Adapted For Patient-Derived Bone Marrow and Peripheral Blood Mononuclear Cells08:50

Colony-Forming Unit Assay Adapted For Patient-Derived Bone Marrow and Peripheral Blood Mononuclear Cells

Published on: June 26, 2026

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...